HOMEVULNERABILITIESCVE-2022-30277
MEDIUM

CVE-2022-30277

CWE-613Published: June 2, 2022· Updated: Jun 17, 2026

5.7
CVSS v3.1

Official Description

BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, including electronic protected health information (ePHI), protected health information (PHI) and personally identifiable information (PII).

NVD Source

Technical Analysis

CVE-2022-30277 requires local access, meaning attackers must already have a foothold on the target system.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), with a CVSS base score of 5.7.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorPhysical
Attack ComplexityLow
Privileges Req.Low
User InteractionRequired
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityNone
CVSS:3.1/AV:P/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N

Affected Vendors & Products

bd1 product(s)
synapsys
Source: NVD CPE · 2 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (2)

Quick Facts

CVE IDCVE-2022-30277
CVSS Score5.7 / 10
SeverityMEDIUM
WeaknessCWE-613
CISA KEVNo
Affected1 vendor(s)
PublishedJun 2, 2022

Related CVEs (CWE-613)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2022-30277 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.